Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
McKinsey
McKesson
Johnson and Johnson
Merck

Last Updated: December 3, 2022

Etonogestrel - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic drug sources for etonogestrel and what is the scope of freedom to operate?

Etonogestrel is the generic ingredient in two branded drugs marketed by Organon and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Etonogestrel has one hundred and five patent family members in thirty-four countries.

There are five drug master file entries for etonogestrel.

Summary for etonogestrel
Recent Clinical Trials for etonogestrel

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Lupin Research IncPhase 2
University of SaskatchewanPhase 2
Saskatchewan Health Authority - Regina AreaPhase 2

See all etonogestrel clinical trials

US Patents and Regulatory Information for etonogestrel

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Organon NEXPLANON etonogestrel IMPLANT;IMPLANTATION 021529-002 May 31, 2011 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Organon IMPLANON etonogestrel IMPLANT;IMPLANTATION 021529-001 Jul 17, 2006 DISCN No No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Organon NEXPLANON etonogestrel IMPLANT;IMPLANTATION 021529-002 May 31, 2011 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Organon NEXPLANON etonogestrel IMPLANT;IMPLANTATION 021529-002 May 31, 2011 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Organon NEXPLANON etonogestrel IMPLANT;IMPLANTATION 021529-002 May 31, 2011 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for etonogestrel

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Organon IMPLANON etonogestrel IMPLANT;IMPLANTATION 021529-001 Jul 17, 2006 See Plans and Pricing See Plans and Pricing
Organon IMPLANON etonogestrel IMPLANT;IMPLANTATION 021529-001 Jul 17, 2006 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for etonogestrel

Country Patent Number Title Estimated Expiration
Ukraine 86404 РЕНТГЕНОКОНТРАСТНОЕ СРЕДСТВО СНАБЖЕНИЯ ЛЕКАРСТВА;РЕНТГЕНОКОНТРАСТНИЙ ЗАСІБ ПОСТАЧАННЯ ЛІКІВ (Normal;heading 1;heading 2;X-RAY VISIBLE DRUG DELIVERY DEVICE) See Plans and Pricing
Norway 20073749 See Plans and Pricing
Slovenia 1729819 See Plans and Pricing
Norway 20073748 See Plans and Pricing
South Korea 20070102718 APPLICATOR FOR INSERTING AN IMPLANT See Plans and Pricing
South Africa 200705962 Applicator for inserting an implant See Plans and Pricing
Denmark 1729819 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for etonogestrel

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0303306 SPC/GB99/044 United Kingdom See Plans and Pricing PRODUCT NAME: ETONOGESTREL; REGISTERED: NL RGV21168 19980825; UK 00065/0161 19990609
0303306 099C0041 Belgium See Plans and Pricing PRODUCT NAME: ETONOGESTREL; NATL. REGISTRATION NO/DATE: 52 IS 296 F 14 19990531; FIRST REGISTRATION: NL RVG 21168 19980825
0303306 29/1999 Austria See Plans and Pricing PRODUCT NAME: ETONOGESTREL; NAT. REGISTRATION NO/DATE: 1-22964 19990330; FIRST REGISTRATION: NL 21168 19980825
0303306 C980027 Netherlands See Plans and Pricing PRODUCT NAME: ETONOGESTREL; REGISTRATION NO/DATE: RVG 21168 19980825
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Dow
Harvard Business School
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.